Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Equity Ratio (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Equity Ratio for 6 consecutive years, with 0.7 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 5.8% year-over-year to 0.7, compared with a TTM value of 0.7 through Sep 2025, down 5.8%, and an annual FY2024 reading of 0.74, up 21.43% over the prior year.
  • Equity Ratio was 0.7 for Q3 2025 at Ovid Therapeutics, down from 0.72 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.95 in Q3 2021 and bottomed at 0.59 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.8, with a median of 0.81 recorded in 2023.
  • The sharpest move saw Equity Ratio skyrocketed 60.78% in 2021, then fell 29.5% in 2024.
  • Year by year, Equity Ratio stood at 0.92 in 2021, then fell by 7.79% to 0.85 in 2022, then dropped by 28.44% to 0.61 in 2023, then grew by 21.43% to 0.74 in 2024, then decreased by 5.43% to 0.7 in 2025.
  • Business Quant data shows Equity Ratio for OVID at 0.7 in Q3 2025, 0.72 in Q2 2025, and 0.73 in Q1 2025.